Related Experiment Video
Updated: Jul 14, 2026

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
Pneumococcal LytA autolysin, a potent therapeutic agent in experimental peritonitis-sepsis caused by highly
Violeta Rodríguez-Cerrato1, Pedro García, Lorena Huelves
1Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz, Avenida de Reyes Católicos 2, 28040 Madrid, Spain.
Abstract:
The in vitro and in vivo antipneumococcal activities of the main pneumococcal autolysin (LytA) and Cpl-1, a lysozyme encoded by phage Cp-1, were studied. Intraperitoneal therapy with LytA or high-dose Cpl-1 remarkably reduced peritoneal bacterial counts (>5 log(10) CFU/ml) compared with those for the controls. After intravenous injection, LytA was the most effective treatment.
More Related Videos
Related Concept Videos
Atypical Pneumonia
Inhibitors of Gram-positive Cell Wall Synthesis
Acute Pyelonephritis II: Diagnostic Studies and Management
Inhibitors of Bacterial Protein Synthesis
Pneumonia I: Introduction
Bacterial Phylum Spirochaetes

